APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Vaccine

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.

23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).

Selected research

Market Analysis & Forecast

Global Pneumococcal Vaccine Market Analysis and Forecast 2026-2032

25 December 2025196 pages

Choose your research edition.

Industry ResearchPneumococcal Vaccine Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Pneumococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Vaccine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.

There are two types of Pneumococcal Vaccine: conjugate vaccines and polysaccharide vaccines.

23-Valent Pneumococcal Polysaccharide Vaccine (PPSV 23) is polysaccharide vaccine. Pneumococcal conjugate vaccines contain PCV 7/13 (Pfizer) and PCV10 (GSK).

Read the full market overview

At present, only MSD, Sanofipasteur and CDIBP can produce PPSV 23, and they hold key technologies and patents, with high-end customers, have been formed in the monopoly position in the industry. As for PCV 13, only Pfizer can supply it. And GSK is the only one manufacturing PCV 10. However, there are some companies working on research of Pneumococcal Vaccine. Pfizer is the leader of this industry with 84% market shares.

North America is the largest consumption market of Pneumococcal Vaccine with sales market share nearly 40%. The second place is Europe, following North America with sales market share over 18%. Asia-Pacific is another important market of Pneumococcal Vaccine, enjoy nearly 16% sales market share, but the consumption experienced a sharp decrease due to approval of government departments in last few years.

This report presents an overview of global market for Pneumococcal Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Pneumococcal Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumococcal Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pneumococcal Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pneumococcal Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pneumococcal Vaccine sales, projected growth trends, production technology, application and end-user industry.

Pneumococcal Vaccine Segment by Company

Pfizer

GSK

MSD

Sanofipasteur

CDIBP

Pneumococcal Vaccine Segment by Type

PPSV 23

PCV 7/13

PCV 10

Pneumococcal Vaccine Segment by End User

Child

Adult

Pneumococcal Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Pneumococcal Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Pneumococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Pneumococcal Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. PPSV 23 Major Manufacturers Table 3. PCV 7/13 Major Manufacturers Table 4. PCV 10 Major Manufacturers Table 5. Global Pneumococcal Vaccine Market Size Growth Rate by End User (US$ Million), 2021 VS 2025 VS 2032 Table 6. Child Major Manufacturers Table 7. Adult Major Manufacturers Table 8. Pneumococcal Vaccine Industry Trends Table 9. Pneumococcal Vaccine Industry Drivers Table 10. Pneumococcal Vaccine Industry Opportunities and Challenges Table 11. Pneumococcal Vaccine Industry Restraints Table 12. Global Pneumococcal Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Pneumococcal Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Pneumococcal Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Pneumococcal Vaccine Revenue Market Share by Region (2021-2026) Table 16. Global Pneumococcal Vaccine Revenue Market Share by Region (2027-2032) Table 17. Global Pneumococcal Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Doses) Table 18. Global Pneumococcal Vaccine Sales by Region (2021-2026) & (K Doses) Table 19. Global Pneumococcal Vaccine Sales by Region (2027-2032) & (K Doses) Table 20. Global Pneumococcal Vaccine Sales Market Share by Region (2021-2026) Table 21. Global Pneumococcal Vaccine Sales Market Share by Region (2027-2032) Table 22. Global Pneumococcal Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Pneumococcal Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Pneumococcal Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Pneumococcal Vaccine Sales Market Share by Manufacturers (2021-2026) Table 26. Global Pneumococcal Vaccine Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 27. Global Pneumococcal Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Pneumococcal Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Pneumococcal Vaccine Manufacturers, Product Type & Application Table 30. Global Pneumococcal Vaccine Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Pneumococcal Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Pneumococcal Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pneumococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Pneumococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Pneumococcal Vaccine Revenue Market Share by Type (2021-2026) Table 37. Global Pneumococcal Vaccine Revenue Market Share by Type (2027-2032) Table 38. Global Pneumococcal Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Doses) Table 39. Global Pneumococcal Vaccine Sales by Type (2021-2026) & (K Doses) Table 40. Global Pneumococcal Vaccine Sales by Type (2027-2032) & (K Doses) Table 41. Global Pneumococcal Vaccine Sales Market Share by Type (2021-2026) Table 42. Global Pneumococcal Vaccine Sales Market Share by Type (2027-2032) Table 43. Global Pneumococcal Vaccine Price by Type (2021-2026) & (USD/Dose) Table 44. Global Pneumococcal Vaccine Price by Type (2027-2032) & (USD/Dose) Table 45. Global Pneumococcal Vaccine Revenue by End User 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Pneumococcal Vaccine Revenue by End User (2021-2026) & (US$ Million) Table 47. Global Pneumococcal Vaccine Revenue by End User (2027-2032) & (US$ Million) Table 48. Global Pneumococcal Vaccine Revenue Market Share by End User (2021-2026) Table 49. Global Pneumococcal Vaccine Revenue Market Share by End User (2027-2032) Table 50. Global Pneumococcal Vaccine Sales by End User 2021 VS 2025 VS 2032 (K Doses) Table 51. Global Pneumococcal Vaccine Sales by End User (2021-2026) & (K Doses) Table 52. Global Pneumococcal Vaccine Sales by End User (2027-2032) & (K Doses) Table 53. Global Pneumococcal Vaccine Sales Market Share by End User (2021-2026) Table 54. Global Pneumococcal Vaccine Sales Market Share by End User (2027-2032) Table 55. Global Pneumococcal Vaccine Price by End User (2021-2026) & (USD/Dose) Table 56. Global Pneumococcal Vaccine Price by End User (2027-2032) & (USD/Dose) Table 57. Pfizer Company Information Table 58. Pfizer Business Overview Table 59. Pfizer Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 60. Pfizer Pneumococcal Vaccine Product Portfolio Table 61. Pfizer Recent Development Table 62. GSK Company Information Table 63. GSK Business Overview Table 64. GSK Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 65. GSK Pneumococcal Vaccine Product Portfolio Table 66. GSK Recent Development Table 67. MSD Company Information Table 68. MSD Business Overview Table 69. MSD Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 70. MSD Pneumococcal Vaccine Product Portfolio Table 71. MSD Recent Development Table 72. Sanofipasteur Company Information Table 73. Sanofipasteur Business Overview Table 74. Sanofipasteur Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 75. Sanofipasteur Pneumococcal Vaccine Product Portfolio Table 76. Sanofipasteur Recent Development Table 77. CDIBP Company Information Table 78. CDIBP Business Overview Table 79. CDIBP Pneumococcal Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 80. CDIBP Pneumococcal Vaccine Product Portfolio Table 81. CDIBP Recent Development Table 82. North America Pneumococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Pneumococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Pneumococcal Vaccine Sales by Type (2021-2026) & (K Doses) Table 85. North America Pneumococcal Vaccine Sales by Type (2027-2032) & (K Doses) Table 86. North America Pneumococcal Vaccine Sales Price by Type (2021-2026) & (USD/Dose) Table 87. North America Pneumococcal Vaccine Sales Price by Type (2027-2032) & (USD/Dose) Table 88. North America Pneumococcal Vaccine Revenue by End User (2021-2026) & (US$ Million) Table 89. North America Pneumococcal Vaccine Revenue by End User (2027-2032) & (US$ Million) Table 90. North America Pneumococcal Vaccine Sales by End User (2021-2026) & (K Doses) Table 91. North America Pneumococcal Vaccine Sales by End User (2027-2032) & (K Doses) Table 92. North America Pneumococcal Vaccine Sales Price by End User (2021-2026) & (USD/Dose) Table 93. North America Pneumococcal Vaccine Sales Price by End User (2027-2032) & (USD/Dose) Table 94. North America Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Pneumococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 96. North America Pneumococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 97. North America Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 98. North America Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 99. North America Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 100. North America Pneumococcal Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 101. North America Pneumococcal Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 102. United States Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 103. Canada Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 104. Mexico Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 105. Europe Pneumococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 106. Europe Pneumococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 107. Europe Pneumococcal Vaccine Sales by Type (2021-2026) & (K Doses) Table 108. Europe Pneumococcal Vaccine Sales by Type (2027-2032) & (K Doses) Table 109. Europe Pneumococcal Vaccine Sales Price by Type (2021-2026) & (USD/Dose) Table 110. Europe Pneumococcal Vaccine Sales Price by Type (2027-2032) & (USD/Dose) Table 111. Europe Pneumococcal Vaccine Revenue by End User (2021-2026) & (US$ Million) Table 112. Europe Pneumococcal Vaccine Revenue by End User (2027-2032) & (US$ Million) Table 113. Europe Pneumococcal Vaccine Sales by End User (2021-2026) & (K Doses) Table 114. Europe Pneumococcal Vaccine Sales by End User (2027-2032) & (K Doses) Table 115. Europe Pneumococcal Vaccine Sales Price by End User (2021-2026) & (USD/Dose) Table 116. Europe Pneumococcal Vaccine Sales Price by End User (2027-2032) & (USD/Dose) Table 117. Europe Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe Pneumococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 119. Europe Pneumococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 120. Europe Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 121. Europe Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 122. Europe Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 123. Europe Pneumococcal Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 124. Europe Pneumococcal Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 125. Germany Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 126. France Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 127. U.K. Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 128. Italy Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 129. Russia Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 130. Spain Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 131. Netherlands Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 132. Switzerland Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 133. Sweden Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 134. Poland Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 135. China Pneumococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 136. China Pneumococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 137. China Pneumococcal Vaccine Sales by Type (2021-2026) & (K Doses) Table 138. China Pneumococcal Vaccine Sales by Type (2027-2032) & (K Doses) Table 139. China Pneumococcal Vaccine Sales Price by Type (2021-2026) & (USD/Dose) Table 140. China Pneumococcal Vaccine Sales Price by Type (2027-2032) & (USD/Dose) Table 141. China Pneumococcal Vaccine Revenue by End User (2021-2026) & (US$ Million) Table 142. China Pneumococcal Vaccine Revenue by End User (2027-2032) & (US$ Million) Table 143. China Pneumococcal Vaccine Sales by End User (2021-2026) & (K Doses) Table 144. China Pneumococcal Vaccine Sales by End User (2027-2032) & (K Doses) Table 145. China Pneumococcal Vaccine Sales Price by End User (2021-2026) & (USD/Dose) Table 146. China Pneumococcal Vaccine Sales Price by End User (2027-2032) & (USD/Dose) Table 147. Asia Pneumococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 148. Asia Pneumococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 149. Asia Pneumococcal Vaccine Sales by Type (2021-2026) & (K Doses) Table 150. Asia Pneumococcal Vaccine Sales by Type (2027-2032) & (K Doses) Table 151. Asia Pneumococcal Vaccine Sales Price by Type (2021-2026) & (USD/Dose) Table 152. Asia Pneumococcal Vaccine Sales Price by Type (2027-2032) & (USD/Dose) Table 153. Asia Pneumococcal Vaccine Revenue by End User (2021-2026) & (US$ Million) Table 154. Asia Pneumococcal Vaccine Revenue by End User (2027-2032) & (US$ Million) Table 155. Asia Pneumococcal Vaccine Sales by End User (2021-2026) & (K Doses) Table 156. Asia Pneumococcal Vaccine Sales by End User (2027-2032) & (K Doses) Table 157. Asia Pneumococcal Vaccine Sales Price by End User (2021-2026) & (USD/Dose) Table 158. Asia Pneumococcal Vaccine Sales Price by End User (2027-2032) & (USD/Dose) Table 159. Asia Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Pneumococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. Asia Pneumococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. Asia Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 163. Asia Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 164. Asia Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 165. Asia Pneumococcal Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 166. Asia Pneumococcal Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 167. Japan Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 168. South Korea Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 169. India Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 170. Australia Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 171. Taiwan Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 172. Southeast Asia Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 173. SAMEA Pneumococcal Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 174. SAMEA Pneumococcal Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 175. SAMEA Pneumococcal Vaccine Sales by Type (2021-2026) & (K Doses) Table 176. SAMEA Pneumococcal Vaccine Sales by Type (2027-2032) & (K Doses) Table 177. SAMEA Pneumococcal Vaccine Sales Price by Type (2021-2026) & (USD/Dose) Table 178. SAMEA Pneumococcal Vaccine Sales Price by Type (2027-2032) & (USD/Dose) Table 179. SAMEA Pneumococcal Vaccine Revenue by End User (2021-2026) & (US$ Million) Table 180. SAMEA Pneumococcal Vaccine Revenue by End User (2027-2032) & (US$ Million) Table 181. SAMEA Pneumococcal Vaccine Sales by End User (2021-2026) & (K Doses) Table 182. SAMEA Pneumococcal Vaccine Sales by End User (2027-2032) & (K Doses) Table 183. SAMEA Pneumococcal Vaccine Sales Price by End User (2021-2026) & (USD/Dose) Table 184. SAMEA Pneumococcal Vaccine Sales Price by End User (2027-2032) & (USD/Dose) Table 185. SAMEA Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 186. SAMEA Pneumococcal Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 187. SAMEA Pneumococcal Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 188. SAMEA Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 189. SAMEA Pneumococcal Vaccine Sales by Country (2021-2026) & (K Doses) Table 190. SAMEA Pneumococcal Vaccine Sales by Country (2027-2032) & (K Doses) Table 191. SAMEA Pneumococcal Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 192. SAMEA Pneumococcal Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 193. Brazil Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 194. Argentina Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 195. Chile Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 196. Colombia Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 197. Peru Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 198. Saudi Arabia Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 199. Israel Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 200. UAE Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 201. Turkey Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 202. Iran Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 203. Egypt Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Table 204. Key Raw Materials Table 205. Raw Materials Key Suppliers Table 206. Pneumococcal Vaccine Distributors List Table 207. Pneumococcal Vaccine Customers List Table 208. Research Programs/Design for This Report Table 209. Authors List of This Report Table 210. Secondary Sources Table 211. Primary Sources List of Figures Figure 1. Pneumococcal Vaccine Image Figure 2. Global Pneumococcal Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. PPSV 23 Image Figure 5. PCV 7/13 Image Figure 6. PCV 10 Image Figure 7. Global Pneumococcal Vaccine Market Size Growth Rate by End User (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Pneumococcal Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 9. Child Image Figure 10. Adult Image Figure 11. Global Pneumococcal Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Pneumococcal Vaccine Revenue (2021-2032) & (US$ Million) Figure 13. Global Pneumococcal Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Pneumococcal Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Pneumococcal Vaccine Revenue Market Share by Region (2021-2032) Figure 16. Global Pneumococcal Vaccine Sales (2021-2032) & (K Doses) Figure 17. Global Pneumococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 18. Global Pneumococcal Vaccine Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Pneumococcal Vaccine Sales YoY (2021-2032) & (K Doses) Figure 20. Europe Pneumococcal Vaccine Sales YoY (2021-2032) & (K Doses) Figure 21. China Pneumococcal Vaccine Sales YoY (2021-2032) & (K Doses) Figure 22. Asia (Excluding China) Pneumococcal Vaccine Sales YoY (2021-2032) & (K Doses) Figure 23. South America, Middle East and Africa Pneumococcal Vaccine Sales YoY (2021-2032) & (K Doses) Figure 24. Global Pneumococcal Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Pneumococcal Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Pneumococcal Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Pneumococcal Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Pneumococcal Vaccine Revenue Market Share by Type (2021-2032) Figure 30. Global Pneumococcal Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 31. Global Pneumococcal Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Pneumococcal Vaccine Sales Market Share by Type (2021-2032) Figure 33. Global Pneumococcal Vaccine Revenue by End User (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Pneumococcal Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Pneumococcal Vaccine Revenue Market Share by End User (2021-2032) Figure 36. Global Pneumococcal Vaccine Sales by End User (2021 VS 2025 VS 2032) & (K Doses) Figure 37. Global Pneumococcal Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Pneumococcal Vaccine Sales Market Share by End User (2021-2032) Figure 39. North America Pneumococcal Vaccine Revenue Share by Type (2021-2032) Figure 40. North America Pneumococcal Vaccine Sales Share by Type (2021-2032) Figure 41. North America Pneumococcal Vaccine Revenue Share by End User (2021-2032) Figure 42. North America Pneumococcal Vaccine Sales Share by End User (2021-2032) Figure 43. North America Pneumococcal Vaccine Revenue Share by Country (2021-2032) Figure 44. North America Pneumococcal Vaccine Sales Share by Country (2021-2032) Figure 45. Europe Pneumococcal Vaccine Revenue Share by Type (2021-2032) Figure 46. Europe Pneumococcal Vaccine Sales Share by Type (2021-2032) Figure 47. Europe Pneumococcal Vaccine Revenue Share by End User (2021-2032) Figure 48. Europe Pneumococcal Vaccine Sales Share by End User (2021-2032) Figure 49. Europe Pneumococcal Vaccine Revenue Share by Country (2021-2032) Figure 50. Europe Pneumococcal Vaccine Sales Share by Country (2021-2032) Figure 51. China Pneumococcal Vaccine Revenue Share by Type (2021-2032) Figure 52. China Pneumococcal Vaccine Sales Share by Type (2021-2032) Figure 53. China Pneumococcal Vaccine Revenue Share by End User (2021-2032) Figure 54. China Pneumococcal Vaccine Sales Share by End User (2021-2032) Figure 55. Asia Pneumococcal Vaccine Revenue Share by Type (2021-2032) Figure 56. Asia Pneumococcal Vaccine Sales Share by Type (2021-2032) Figure 57. Asia Pneumococcal Vaccine Revenue Share by End User (2021-2032) Figure 58. Asia Pneumococcal Vaccine Sales Share by End User (2021-2032) Figure 59. Asia Pneumococcal Vaccine Revenue Share by Country (2021-2032) Figure 60. Asia Pneumococcal Vaccine Sales Share by Country (2021-2032) Figure 61. SAMEA Pneumococcal Vaccine Revenue Share by Type (2021-2032) Figure 62. SAMEA Pneumococcal Vaccine Sales Share by Type (2021-2032) Figure 63. SAMEA Pneumococcal Vaccine Revenue Share by End User (2021-2032) Figure 64. SAMEA Pneumococcal Vaccine Sales Share by End User (2021-2032) Figure 65. SAMEA Pneumococcal Vaccine Revenue Share by Country (2021-2032) Figure 66. SAMEA Pneumococcal Vaccine Sales Share by Country (2021-2032) Figure 67. Pneumococcal Vaccine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Pneumococcal Vaccine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • PPSV 23
  • PCV 7/13
  • PCV 10
Applications
  • Child
  • Adult
Companies covered
  • Pfizer
  • GSK
  • MSD
  • Sanofipasteur
  • CDIBP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Pneumococcal Vaccine Market by Type
  3. 1.2.1 Global Pneumococcal Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 PPSV 23
  5. 1.2.3 PCV 7/13
  6. 1.2.4 PCV 10
  7. 1.3 Pneumococcal Vaccine Market by End User
  8. 1.3.1 Global Pneumococcal Vaccine Market Size by End User, 2021 VS 2025 VS 2032
  9. 1.3.2 Child
  10. 1.3.3 Adult
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Pneumococcal Vaccine Market Dynamics
  1. 2.1 Pneumococcal Vaccine Industry Trends
  2. 2.2 Pneumococcal Vaccine Industry Drivers
  3. 2.3 Pneumococcal Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Pneumococcal Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Pneumococcal Vaccine Revenue by Region
  3. 3.2.1 Global Pneumococcal Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Pneumococcal Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Pneumococcal Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Pneumococcal Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Pneumococcal Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Pneumococcal Vaccine Sales by Region
  9. 3.4.1 Global Pneumococcal Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Pneumococcal Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Pneumococcal Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Pneumococcal Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Pneumococcal Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Pneumococcal Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Pneumococcal Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Pneumococcal Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Pneumococcal Vaccine Sales by Manufacturers
  6. 4.2.1 Global Pneumococcal Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Pneumococcal Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Pneumococcal Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Pneumococcal Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Pneumococcal Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Pneumococcal Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Pneumococcal Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Pneumococcal Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Pneumococcal Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Pneumococcal Vaccine Tier 1, Tier 2, and Tier 3
5 Pneumococcal Vaccine Market by Type
  1. 5.1 Global Pneumococcal Vaccine Revenue by Type
  2. 5.1.1 Global Pneumococcal Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Pneumococcal Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Pneumococcal Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Pneumococcal Vaccine Sales by Type
  6. 5.2.1 Global Pneumococcal Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumococcal Vaccine Sales by Type (2021-2032) & (K Doses)
  8. 5.2.3 Global Pneumococcal Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Pneumococcal Vaccine Price by Type
6 Pneumococcal Vaccine Market by Application
  1. 6.1 Global Pneumococcal Vaccine Revenue by Application
  2. 6.1.1 Global Pneumococcal Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Pneumococcal Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Pneumococcal Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Pneumococcal Vaccine Sales by Application
  6. 6.2.1 Global Pneumococcal Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Pneumococcal Vaccine Sales by Application (2021-2032) & (K Doses)
  8. 6.2.3 Global Pneumococcal Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Pneumococcal Vaccine Price by Application
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Pneumococcal Vaccine Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 GSK
  8. 7.2.1 GSK Company Information
  9. 7.2.2 GSK Business Overview
  10. 7.2.3 GSK Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 GSK Pneumococcal Vaccine Product Portfolio
  12. 7.2.5 GSK Recent Developments
  13. 7.3 MSD
  14. 7.3.1 MSD Company Information
  15. 7.3.2 MSD Business Overview
  16. 7.3.3 MSD Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 MSD Pneumococcal Vaccine Product Portfolio
  18. 7.3.5 MSD Recent Developments
  19. 7.4 Sanofipasteur
  20. 7.4.1 Sanofipasteur Company Information
  21. 7.4.2 Sanofipasteur Business Overview
  22. 7.4.3 Sanofipasteur Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sanofipasteur Pneumococcal Vaccine Product Portfolio
  24. 7.4.5 Sanofipasteur Recent Developments
  25. 7.5 CDIBP
  26. 7.5.1 CDIBP Company Information
  27. 7.5.2 CDIBP Business Overview
  28. 7.5.3 CDIBP Pneumococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 CDIBP Pneumococcal Vaccine Product Portfolio
  30. 7.5.5 CDIBP Recent Developments
8 North America
  1. 8.1 North America Pneumococcal Vaccine Market Size by Type
  2. 8.1.1 North America Pneumococcal Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Pneumococcal Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Pneumococcal Vaccine Price by Type (2021-2032)
  5. 8.2 North America Pneumococcal Vaccine Market Size by End User
  6. 8.2.1 North America Pneumococcal Vaccine Revenue by End User (2021-2032)
  7. 8.2.2 North America Pneumococcal Vaccine Sales by End User (2021-2032)
  8. 8.2.3 North America Pneumococcal Vaccine Price by End User (2021-2032)
  9. 8.3 North America Pneumococcal Vaccine Market Size by Country
  10. 8.3.1 North America Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Pneumococcal Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Pneumococcal Vaccine Market Size by Type
  2. 9.1.1 Europe Pneumococcal Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Pneumococcal Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Pneumococcal Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Pneumococcal Vaccine Market Size by End User
  6. 9.2.1 Europe Pneumococcal Vaccine Revenue by End User (2021-2032)
  7. 9.2.2 Europe Pneumococcal Vaccine Sales by End User (2021-2032)
  8. 9.2.3 Europe Pneumococcal Vaccine Price by End User (2021-2032)
  9. 9.3 Europe Pneumococcal Vaccine Market Size by Country
  10. 9.3.1 Europe Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Pneumococcal Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Pneumococcal Vaccine Market Size by Type
  2. 10.1.1 China Pneumococcal Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Pneumococcal Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Pneumococcal Vaccine Price by Type (2021-2032)
  5. 10.2 China Pneumococcal Vaccine Market Size by End User
  6. 10.2.1 China Pneumococcal Vaccine Revenue by End User (2021-2032)
  7. 10.2.2 China Pneumococcal Vaccine Sales by End User (2021-2032)
  8. 10.2.3 China Pneumococcal Vaccine Price by End User (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Pneumococcal Vaccine Market Size by Type
  2. 11.1.1 Asia Pneumococcal Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Pneumococcal Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Pneumococcal Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Pneumococcal Vaccine Market Size by End User
  6. 11.2.1 Asia Pneumococcal Vaccine Revenue by End User (2021-2032)
  7. 11.2.2 Asia Pneumococcal Vaccine Sales by End User (2021-2032)
  8. 11.2.3 Asia Pneumococcal Vaccine Price by End User (2021-2032)
  9. 11.3 Asia Pneumococcal Vaccine Market Size by Country
  10. 11.3.1 Asia Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Pneumococcal Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Pneumococcal Vaccine Market Size by Type
  2. 12.1.1 SAMEA Pneumococcal Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Pneumococcal Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Pneumococcal Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Pneumococcal Vaccine Market Size by End User
  6. 12.2.1 SAMEA Pneumococcal Vaccine Revenue by End User (2021-2032)
  7. 12.2.2 SAMEA Pneumococcal Vaccine Sales by End User (2021-2032)
  8. 12.2.3 SAMEA Pneumococcal Vaccine Price by End User (2021-2032)
  9. 12.3 SAMEA Pneumococcal Vaccine Market Size by Country
  10. 12.3.1 SAMEA Pneumococcal Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Pneumococcal Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Pneumococcal Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Pneumococcal Vaccine Value Chain Analysis
  2. 13.1.1 Pneumococcal Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Pneumococcal Vaccine Production Mode & Process
  6. 13.2 Pneumococcal Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Pneumococcal Vaccine Distributors
  9. 13.2.3 Pneumococcal Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst